An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer

BACKGROUND: Pancreatic cancer is a deadly disease with a very low 5-year patient survival rate of 6–8%. The major challenges of eliminating pancreatic cancer are treatment resistance and stromal barriers to optimal drug access within the tumor. Therefore, effective molecular targeting drugs with hig...

Descripción completa

Detalles Bibliográficos
Autores principales: Ling, Xiang, Wu, Wenjie, Fan, Chuandong, Xu, Chao, Liao, Jianqun, Rich, Laurie J., Huang, Ruea-Yea, Repasky, Elizabeth A., Wang, Xinjiang, Li, Fengzhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169080/
https://www.ncbi.nlm.nih.gov/pubmed/30285798
http://dx.doi.org/10.1186/s13046-018-0899-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169080/
https://www.ncbi.nlm.nih.gov/pubmed/30285798
http://dx.doi.org/10.1186/s13046-018-0899-8

Ejemplares similares